Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors

14 Jul 2018

Abstract excerpt

Bictegravir (BIC) and cabotegravir (CAB) are the latest available HIV integrase inhibitors in clinical trials. The combination of major integrase inhibitor substitutions G140S/Q148H has been shown to confer high-level resistance to the approved integrase inhibitors raltegravir (RAL) and elvitegravir (EVG) but not necessarily dolutegravir (DTG). We assayed recombinant viruses made from patient-derived RNA extracts...

Topics

Join the communities discussing this publication.

Biochemical and Molecular Research
HIV/AIDS drug development and treatment
HIV Research and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30010985
DOI: 10.1093/infdis/jiy428

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase InhibitorsPMID 30010985Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.Semantic proximity Read ↗

Evolution of HIV integrase resistance mutations.Semantic proximity Read ↗

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.Semantic proximity Read ↗

Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.Semantic proximity Read ↗

Resistance to Integrase InhibitorsSemantic proximity Read ↗

HIV drug resistance against strand transfer integrase inhibitors.Semantic proximity Read ↗

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profilesSemantic proximity Read ↗

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.Semantic proximity Read ↗

Resistance to HIV integrase inhibitorsSemantic proximity Read ↗

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical IsolatesSemantic proximity Read ↗

High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.